ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
April 13, 2021 16:15 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ForeseeHome AMD home monitoring real-world data analysis demonstrates substantial benefit for patients’ vision
April 06, 2021 08:00 ET
|
Notal Vision
Manassas, VA, April 06, 2021 (GLOBE NEWSWIRE) -- Real-world data on the performance of the ForeseeHome® AMD Monitoring Program, a home-based diagnostic that helps detect the conversion from...
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 05, 2021 16:15 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative...
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
March 31, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for...
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
March 29, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., SHANGHAI, China and PRINCETON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a...
Visionary Ventures Closes Fund II with $114MM in Committed Capital
March 23, 2021 09:17 ET
|
Visionary Venture Fund
Aliso Viejo, California, March 23, 2021 (GLOBE NEWSWIRE) -- Visionary Ventures today announced the closing of Visionary Venture Fund II with $114MM in committed capital. The Fund, which was strongly...
Nextech Announces Registration Launch For Virtual User Conference: Edge 2021
March 17, 2021 11:44 ET
|
Nextech Systems, Inc.
TAMPA, Fla., March 17, 2021 (GLOBE NEWSWIRE) -- Nextech Systems, a leading provider of healthcare technology solutions for specialty physician practices, today opened registration for its seventh...
Ophthalmology Market Value Anticipated To Reach US$ 64.3 Billion By 2027: Acumen Research And Consulting
March 17, 2021 11:35 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Ophthalmology Market– Global Industry Analysis, Market Size, Opportunities and...
Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 10, 2021 16:05 ET
|
Clearside Biomedical, Inc.
- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - - Initial Safety Data from OASIS Trial Expected Mid-2021 - - Four Ongoing Internal & Partner Clinical Trials Using...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
March 09, 2021 07:30 ET
|
Graybug Vision, Inc.
Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...